Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy

Inclusion Criteria

• •Have participated to a study that meets the following criteria:
• •Be a study of retigabine, eslicarbazepine, lacosamide, zonisamide, pregabalin or tiagabine as an adjuvant therapy, compared to placebo or another drug;
• •Be a randomized, placebo-controlled, add-on trial, or a parallel trial or cross-over trial in which data from the first treatment period could be treated as a parallel study;
• •Have recruited patients with drug-resistant partial epilepsy (i.e., simple partial, complex partial, and/or secondarily generalised tonic-clonic seizures not controlled by at least 1 or more other AEDs);
• •Have a maintenance treatment period of 8 weeks or longer, with a prospective baseline of minimum 4 weeks.